Valneva SE
NASDAQ:VALNBiotechnology
+$0.01 today
- Market cap
- $510.36M
- Beta
- 1.40
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.80
Volume 0.00M
Average 0.09M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Valneva SE
NASDAQ:VALN
Intrinsic Alpha fair value
Locked
Current Price
$5.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -21.5% | +19.7% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -21.5% over three years. Forward estimates point to Revenue at +19.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Moderna, Inc. NASDAQ:MRNA | $90.38B | $223.37 | Not rated | -7.9 | +791.46% |
Vaxcyte, Inc. NASDAQ:PCVX | $10.03B | $63.37 | Not rated | -7.8 | +22.43% |
ImmunityBio, Inc. NASDAQ:IBRX | $6.40B | $6.02 | Not rated | -8.6 | +225.25% |
Vir Biotechnology, Inc. NASDAQ:VIR | $1.71B | $9.96 | Not rated | -3.0 | +59.53% |
Novavax, Inc. NASDAQ:NVAX | $1.41B | $8.53 | Not rated | -17.3 | +24.12% |
Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | $240.96M | $8.36 | Not rated | -2.7 | +28.81% |
Inovio Pharmaceuticals, Inc. NASDAQ:INO | $98.80M | $1.43 | Not rated | -8.9 | -1.16% |
Continue the stock analysis
Jump to another research area for this company.